Geode Capital Management’s INmune Bio INMB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $901K | Buy |
389,931
+25,069
| +7% | +$57.9K | ﹤0.01% | 3358 |
|
|
2025
Q1 | $2.85M | Buy |
364,862
+1,260
| +0.3% | +$9.84K | ﹤0.01% | 2914 |
|
|
2024
Q4 | $1.7M | Buy |
363,602
+19,136
| +6% | +$89.4K | ﹤0.01% | 3189 |
|
|
2024
Q3 | $1.86M | Buy |
344,466
+21,262
| +7% | +$115K | ﹤0.01% | 3150 |
|
|
2024
Q2 | $2.85M | Buy |
323,204
+152,402
| +89% | +$1.34M | ﹤0.01% | 3008 |
|
|
2024
Q1 | $2.01M | Buy |
170,802
+762
| +0.4% | +$8.96K | ﹤0.01% | 3107 |
|
|
2023
Q4 | $1.91M | Buy |
170,040
+2,937
| +2% | +$33.1K | ﹤0.01% | 3114 |
|
|
2023
Q3 | $1.14M | Buy |
167,103
+12,423
| +8% | +$85K | ﹤0.01% | 3267 |
|
|
2023
Q2 | $1.4M | Buy |
154,680
+11,023
| +8% | +$100K | ﹤0.01% | 3226 |
|
|
2023
Q1 | $928K | Buy |
143,657
+660
| +0.5% | +$4.26K | ﹤0.01% | 3382 |
|
|
2022
Q4 | $906K | Buy |
142,997
+3,391
| +2% | +$21.5K | ﹤0.01% | 3386 |
|
|
2022
Q3 | $865K | Buy |
139,606
+1,382
| +1% | +$8.56K | ﹤0.01% | 3467 |
|
|
2022
Q2 | $1.22M | Buy |
138,224
+10,695
| +8% | +$94.5K | ﹤0.01% | 3332 |
|
|
2022
Q1 | $1.07M | Buy |
127,529
+9,259
| +8% | +$77.9K | ﹤0.01% | 3588 |
|
|
2021
Q4 | $1.21M | Buy |
118,270
+28,663
| +32% | +$292K | ﹤0.01% | 3624 |
|
|
2021
Q3 | $1.74M | Buy |
89,607
+15,813
| +21% | +$307K | ﹤0.01% | 3419 |
|
|
2021
Q2 | $1.3M | Buy |
73,794
+12,957
| +21% | +$228K | ﹤0.01% | 3473 |
|
|
2021
Q1 | $722K | Buy |
60,837
+27,182
| +81% | +$323K | ﹤0.01% | 3682 |
|
|
2020
Q4 | $579K | Buy |
33,655
+3,632
| +12% | +$62.5K | ﹤0.01% | 3545 |
|
|
2020
Q3 | $309K | Buy |
+30,023
| New | +$309K | ﹤0.01% | 3586 |
|